Source: Eur Respir J 2011; 37: 823-834
Disease area: Airway diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
De Cunto G., Cardini S., Cirino G., Geppetti P., Lungarella G., Lucattelli M.. Pulmonary hypertension in smoking mice over-expressing protease-activated receptor-2. Eur Respir J 2011; 37: 823-834

Member's Comments

No comment yet.

Related content which might interest you: Siah2 in pulmonary hypertension and right ventricular hypertrophy Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013 In a model of genetic pulmonary hypertension, VIP attenuates pulmonary vascular remodeling and right ventricular hypertrophy Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension Year: 2007 Effects of cigarette smoke and hypoxia on pulmonary circulation in the guinea pig Source: Eur Respir J 2011; 38: 617-627 Year: 2011 Cigarette smoke exposure induces endothelial dysfunction in pulmonary arteries in the guinea pig Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology Year: 2005 Cigarette smoke-induced pulmonary inflammation, but not airway wall remodeling, is attenuated in CCR5 deficient mice Source: Annual Congress 2007 - The best of airway epithelial cells Year: 2007 Chronic thromboembolic pulmonary hypertension: animal models Source: Eur Respir J 2013; 41: 1200-1206 Year: 2013 Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2013; 41: 224-232 Year: 2013 Protease-activated receptor-2 (PAR-2) overexpression induces pulmonary hypertension and vascular structural changes in mice chronically exposed to cigarette smoke Source: Annual Congress 2008 - Vascular and interstitial remodelling in chronic lung disease: therapeutic interventions on the horizon Year: 2008 Human apyrase (APT102) treatment attenuates the development of severe pulmonary arterial hypertension (PAH) Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013 Targeting aquaporin 1 reverses hypoxia-induced pulmonary hypertension in mice Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 Cigarette smoke induced pulmonary emphysema is attenuated in CCR6 deficient mice Source: Annual Congress 2006 - Cell biology of asthma and COPD Year: 2006 Right ventricular lymphatic insufficiency is associated with increased edema in pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013 IL-6 receptor overexpression in pulmonary arterial smooth muscle cells in idiopathic pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Phosphodiesterase inhibitors as promising therapies for cigarette smoke-induced emphysema and pulmonary hypertension (PH) in mice Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Renal denervation reduces pulmonary vascular remodeling in two experimental pulmonary arterial hypertension models Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition Source: Eur Respir J 2008; 31: 599-610 Year: 2008 Expression and function of aquaporin 1 in hypoxia-induced pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension Source: Eur Respir J 2009; 34: 662 Year: 2009 Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD Source: Eur Respir J 2002; 19: 632-638 Year: 2002 Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats Source: Eur Respir J 2011; 37: 1104-1118 Year: 2011